Drug Trial Radar · NCT07477743
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
331
Planned (sponsor's estimate)
Start
Mar 17, 2026
Primary completion
Dec 31, 2027
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- HC Biopharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced gastrointestinal cancer and determine the recommended dose for subsequent studies.
Conditions
- Advanced Solid Tumor Cancer
Interventions
HC010Drug
HC010 once every 3 weeks (Q3W) by intravenous drip
PaclitaxelDrug
the combination chemotherapy regimens are all commonly used in clinical practice
OxaliplatinDrug
the combination chemotherapy regimens are all commonly used in clinical practice
CapecitabineDrug
the combination chemotherapy regimens are all commonly used in clinical practice
HC006Drug
HC006 once every 3 weeks (Q3W) by intravenous drip
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs)Time frame: From first dose to 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.